TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03912493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Game Based Virtual Reality Exercises
Description: A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy and Rehabilitation
Description: The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy and Rehabilitation
Description: The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
Study: NCT00979823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early SimCare Diabetes Group
Description: Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed SimCare Diabetes Group
Description: Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
Study: NCT03324438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Telehealth T1D C2oYoT1-HR
Description: 1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
Study: NCT02162771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study: NCT02565901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT01776021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cranberry juice
Description: cranberry juice beverage at a dose of one 8 oz. beverage per day for six months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo beverage
Description: placebo beverage at a dose of one 8 oz. beverage per day for six months
Study: NCT03391765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution for IV infusion on Day 15
Description: 0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution for IV infusion on Day 15
Description: 0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
Study: NCT02212444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic elastomeric fabric orthoses (DEFO)
Description: A patient customised dynamic elastomeric fabric orthoses (DEFO)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off -the-shelf triplanar orthoses
Study: NCT02259517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
Study: NCT00963911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric screening tests
Description: The G-8 consists of eight items: patient age (\>85, 80-85, \<80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was \<=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score \>=3 was considered to show impairment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional geriatric assessment
Description: Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
Study: NCT00551070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study: NCT03966053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Description: Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Description: Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Description: Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Description: Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
Study: NCT01073670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen & Indomethacin
Description: Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Study: NCT05011643

Intervention type: OTHER
Intervention: Moderate-intensity exercise
Description: Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.

Intervention type: OTHER
Intervention: Moderate-intensity exercise
Description: Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.

Intervention type: OTHER
Intervention: Moderate-intensity exercise
Description: Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
Study: NCT02104362

Intervention type: RADIATION
Group type: OTHER
Intervention: exclusive single-fraction irradiation
Study: NCT01750762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT03484676

Intervention type: DEVICE
Group type: OTHER
Intervention: Titinium
Description: custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
Study: NCT02056860

Intervention type: PROCEDURE
Intervention: Group 1 will receive 15 Hz
Description: Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.

Intervention type: PROCEDURE
Intervention: Group 2 will receive 30 Hz
Description: Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.

Intervention type: PROCEDURE
Intervention: Group 3 will receive 60 Hz
Description: Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.

Intervention type: PROCEDURE
Intervention: Group 4 will receive 100 Hz
Description: Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.

Intervention type: PROCEDURE
Intervention: Phase II Optimal Frequency
Description: Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
Study: NCT02016404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-sodium, high-potassium salt
Description: Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular salt
Description: Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
Study: NCT02628002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill (Alter-G)
Description: Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treadmill/regadenoson
Description: Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
Study: NCT03326310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
Study: NCT00485225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3270
Description: Transdermal Therapeutic System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3270
Description: Transdermal Therapeutic System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3270
Description: Transdermal Therapeutic System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3270
Description: Transdermal Therapeutic System
Study: NCT03996408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT01124721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive computerized training for several days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training-placebo
Description: Cognitive training that only minimally increases in difficulty
Study: NCT03083535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing
Description: Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing
Description: Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Brushing
Description: Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aloe vera Massaging
Description: Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aloe vera Massaging
Description: Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
Study: NCT05892211

Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Pittsburgh Sleep Quality Index (PSQI) is done by each participant to assess the sleep quality and disturbances before thepolysomnography test.
Study: NCT03083535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP with aloe vera massaging
Description: on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
Study: NCT01933295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy
Study: NCT03873220

Intervention type: DEVICE
Intervention: Wrist Actigraphy Devices
Description: A watch-like wearable sensor

Intervention type: DEVICE
Intervention: Sleep Monitor
Description: Remote Sensor

Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep Monitor

Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera
Study: NCT00409695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Thymoglobulin (ATG)
Description: 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Thymoglobulin (ATG)
Description: 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
Study: NCT01500330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cupping massage
Description: the upper back is covered in massage oil the cupping glass is drawn along the back muscles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: standardized programme on muscle relaxation according to Jacobson
Study: NCT02364180

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electromyography (EMG)
Study: NCT03873818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03887195

Intervention type: OTHER
Intervention: Training mandatory module about the therapeutic relationship
Description: The training programme is composed by:~* 2 lectures (optional)~* 6 supervision sessions by Balint type groups (5 of which are mandatory);~* 5 role-plays (all required);~* 2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination.
Study: NCT03752541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-UCART
Description: A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
Study: NCT01673009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.